IDNA News and Press, iShares Genomics Immunology and Healthcare From 01/02/21

Gainers: S&P Biotech Bear 3X Direxion (LABD) +22.6%.South Korea Bull 3X Direxion (KORU) +20.0%.Utilities Bull 3X Direxion (UTSL) +9.6%.CSI 300 China A 2X Direxion (CHAU) +9.2%.Semiconductor Bull 3X Direxion (SOXL) +7.9%.Losers: S&P Biotech Bull 3X Direxion (LA...

Average analyst S&P 500 forecasts and S&P history Factoids: 2020 operating earnings: -21.1% and revenue: -3.7% 2021 operating earnings: +28.0% and revenue: +8.4% Net effect (2021 vs 2019): 2-year earnings about 1% higher and revenue about 4% higher. Standard & Poorȁ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good way to enter th...

In my last article titled “ ACADIA: The company perspectives in numbers ”, I described the demographic trends that the company is operating under, listed key near-term catalysts, and made an overview of the company’s development. However, in the comments to the article, I ...

I treat ACADIA Pharmaceuticals as an attractive long-term investment opportunity based firstly on the demographic trends in the U.S. as well as in the world and secondly on diseases progressing Y/Y for which the company is developing medications. ACADIA is well prepared financially and has t...

Gainers:  DB Crude Oil -2X ETN Powershares (NYSEARCA: DTO )  +81.4% . More news on: DB Crude Oil Double Short ETN, BMO MicroSectors FANG+ Index 3X Leveraged ETN, Direxion Daily S&P Biotech Bull 3x Shares ETF, News on ETFs, Stocks on the move, Read more ...

Broadly, genetics is the study of genes, their variations and hereditary characteristics. As Live Science describes it , genetics involves looking at how traits are passed on through generations. So what is genetics investing? When it comes to genetics investing, companies in this niche li...

High drug prices will, again, be a key issue in the 2020 Presidential campaign considering that President Trump has made scant progress on the matter despite much rhetoric. More news on: Eli Lilly and Company, Merck & Co., Inc., Amgen Inc., Healthcare stocks news, , News on ETFs, R...

Faced with pushback from multiple fronts over high drug prices, biopharmaceutical firms are experimenting with new ways to get paid for their priciest offerings, mostly biologics, in a report from the WSJ. More news on: Alnylam Pharmaceuticals, Inc., Sanofi, Novartis AG, Healthcare stock...

The new budget proposed by California Governor Gavin Newsom includes a plan to allow the state to contract with generic drug makers to provide medicines to all Californians. He believes that the government's purchasing power may be sufficient to cut drug prices to the state's 40M residents...